BR112015014836A2 - método para tratamento alvo de uma ou mais condições do fígado, e, uso oral de uma quantidade terapeuticamente eficaz de pelo menos um análogo de diamidina ou um sal farmaceuticamente aceitável da mesma - Google Patents

método para tratamento alvo de uma ou mais condições do fígado, e, uso oral de uma quantidade terapeuticamente eficaz de pelo menos um análogo de diamidina ou um sal farmaceuticamente aceitável da mesma

Info

Publication number
BR112015014836A2
BR112015014836A2 BR112015014836A BR112015014836A BR112015014836A2 BR 112015014836 A2 BR112015014836 A2 BR 112015014836A2 BR 112015014836 A BR112015014836 A BR 112015014836A BR 112015014836 A BR112015014836 A BR 112015014836A BR 112015014836 A2 BR112015014836 A2 BR 112015014836A2
Authority
BR
Brazil
Prior art keywords
pharmaceutically acceptable
diamidine
effective amount
therapeutically effective
acceptable salt
Prior art date
Application number
BR112015014836A
Other languages
English (en)
Portuguese (pt)
Inventor
Ravenelle François
Colin Patrick
Falardeau Pierre
Original Assignee
Verlyx Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verlyx Pharma Inc filed Critical Verlyx Pharma Inc
Publication of BR112015014836A2 publication Critical patent/BR112015014836A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
BR112015014836A 2012-12-21 2013-12-20 método para tratamento alvo de uma ou mais condições do fígado, e, uso oral de uma quantidade terapeuticamente eficaz de pelo menos um análogo de diamidina ou um sal farmaceuticamente aceitável da mesma BR112015014836A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261745011P 2012-12-21 2012-12-21
PCT/CA2013/051003 WO2014094176A1 (en) 2012-12-21 2013-12-20 Uses and methods for the treatment of liver diseases or conditions

Publications (1)

Publication Number Publication Date
BR112015014836A2 true BR112015014836A2 (pt) 2017-07-11

Family

ID=50977490

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015014836A BR112015014836A2 (pt) 2012-12-21 2013-12-20 método para tratamento alvo de uma ou mais condições do fígado, e, uso oral de uma quantidade terapeuticamente eficaz de pelo menos um análogo de diamidina ou um sal farmaceuticamente aceitável da mesma

Country Status (12)

Country Link
US (2) US9375411B2 (enExample)
EP (1) EP2934501A4 (enExample)
JP (1) JP6370801B2 (enExample)
KR (1) KR20150126595A (enExample)
CN (1) CN104968340A (enExample)
AU (1) AU2013362755B2 (enExample)
BR (1) BR112015014836A2 (enExample)
CA (1) CA2894466A1 (enExample)
HK (1) HK1216721A1 (enExample)
MX (1) MX2015007945A (enExample)
RU (1) RU2015126505A (enExample)
WO (1) WO2014094176A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3668544A1 (en) * 2017-08-15 2020-06-24 Progenity, Inc. Treatment of inflammatory disease using ingestible device to release immune modulator
WO2019095046A1 (en) * 2017-11-16 2019-05-23 Montdorex Inc. Mono- and di-amidine endo-exonuclease inhibitors and methods for inhibiting endo-exonuclease activity
CN110478340A (zh) * 2018-05-14 2019-11-22 复旦大学 喷他嘧啶羟乙基磺酸盐在制备肝癌药物方面的应用
BR112022002962A2 (pt) 2019-08-16 2022-07-05 Applied Molecular Transport Inc Composições, formulações e produção e purificação de interleucina

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA388674A (en) * 1940-05-14 The B. F. Goodrich Company Brake structure
GB1288376A (enExample) 1968-10-29 1972-09-06
DE2833135A1 (de) 1978-07-28 1980-02-07 Henkel Kgaa Verwendung von substituierten oligocarbamidinen als mikrobistatika sowie diese enthaltende antimikrobielle mittel
US5204113A (en) 1987-04-09 1993-04-20 Fisons Plc Pharmaceutical compositions containing pentamidine
US5084480A (en) 1987-11-06 1992-01-28 Fujisawa Usa, Inc. Pentamidine salts useful in the treatment of pneumocystis carinii pneumonia
US4853416A (en) 1988-04-25 1989-08-01 Fisons Corporation Solutions of pentamidine
US5162361A (en) * 1990-04-10 1992-11-10 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Method of treating diseases associated with elevated levels of interleukin 1
DE4321444A1 (de) 1993-06-28 1995-01-05 Bernd Prof Dr Clement Pharmazeutische Zubereitung
JPH08333324A (ja) 1995-06-08 1996-12-17 Terumo Corp ベンゼン誘導体およびそれを含有する医薬製剤
JP3540457B2 (ja) 1995-09-11 2004-07-07 テルモ株式会社 抗血栓性を賦与した医療用基材
CA2350801C (en) 1998-11-10 2008-05-20 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines
US7884090B2 (en) 1999-03-17 2011-02-08 Ernest L. Bonner, Jr. Compositions and methods for the treatment of arthritis
US7115665B1 (en) 2000-11-16 2006-10-03 Onocozyme Pharma, Inc. Inhibitors of endo-exonuclease activity for treating cancer
US6569853B1 (en) 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US6693125B2 (en) 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
US20040010045A1 (en) 2001-09-07 2004-01-15 Taolin Yi Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
EP1572070A4 (en) 2001-09-07 2009-11-04 Cleveland Clinic Foundation THERAPEUTIC COMPOSITIONS AND METHOD FOR MODULATING PROTEIN TYROSINE PHOSPHATASES
AU2003241346A1 (en) * 2002-05-01 2003-11-17 The Cleveland Clinic Foundation Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
US20050054708A1 (en) 2003-07-28 2005-03-10 Nichols Matthew James Combinations of drugs for the treatment of neoplasms
US7994225B2 (en) 2004-03-17 2011-08-09 Rempex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections
EP1732527A2 (en) 2004-03-17 2006-12-20 Mpex Pharmaceuticals, Inc. Use and administration of bacterial efflux pump inhibitors
EP1817018A4 (en) 2004-11-12 2009-10-14 Mediquest Therapeutics Inc HYDROPHOBIC POLYAMINE AMIDES, POWERFUL SEQUESTERS OF LIPOPOLYSACCHARIDES
TW200719903A (en) 2005-04-19 2007-06-01 Combinatorx Inc Compositions for the treatment of neoplasms
US7199267B1 (en) 2005-10-21 2007-04-03 Mediquest Therapeutics, Inc. Recognition of oligiosaccaride molecular targets by polycationic small molecule inhibitors and treatment of immunological disorders and infectious diseases
US20070197658A1 (en) 2006-02-22 2007-08-23 David Sunil A Polyamines and their use as antibacterial and sensitizing agents
US20080226596A1 (en) 2006-06-19 2008-09-18 Taolin Yi Therapeutic compositions and methods useful in treating hepatitis
DE102008007381A1 (de) * 2008-02-01 2009-08-13 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg Amidine und Guanidine und deren Derivate zur Behandlung von Krankheiten
DE102008007426A1 (de) 2008-02-01 2009-08-06 Rheinische Friedrich-Wilhelms-Universität Bonn Unbenetzbare Oberflächen
US8436049B2 (en) 2008-02-21 2013-05-07 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Uses of pentamidine and related compounds
RU2011142806A (ru) 2009-05-01 2013-06-10 ОНКОЗИМ ФАРМА ИНК. (Канада) Комбинации пентамидина для лечения рака
WO2011035225A1 (en) 2009-09-21 2011-03-24 President And Fellows Of Harvard College Synergistic combination therapy
WO2012044936A1 (en) 2010-09-30 2012-04-05 Portola Pharmaceuticals, Inc. Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide
PL2550963T3 (pl) * 2011-07-25 2017-08-31 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg Estry kwasu amidooksymokarboksylowego pentamidyny jako proleki i ich zastosowanie jako leki
WO2014009592A1 (en) * 2012-07-11 2014-01-16 Waterbox Oy Apparatus for providing rotating movement

Also Published As

Publication number Publication date
CN104968340A (zh) 2015-10-07
AU2013362755A1 (en) 2015-07-02
US20150297540A1 (en) 2015-10-22
US9827211B2 (en) 2017-11-28
WO2014094176A1 (en) 2014-06-26
CA2894466A1 (en) 2014-06-26
EP2934501A1 (en) 2015-10-28
EP2934501A4 (en) 2016-06-01
RU2015126505A (ru) 2017-01-27
JP6370801B2 (ja) 2018-08-08
MX2015007945A (es) 2016-02-16
HK1216721A1 (zh) 2016-12-02
US20160287535A1 (en) 2016-10-06
JP2016503035A (ja) 2016-02-01
KR20150126595A (ko) 2015-11-12
AU2013362755B2 (en) 2018-09-13
US9375411B2 (en) 2016-06-28

Similar Documents

Publication Publication Date Title
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
GT201300243A (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112014003225A2 (pt) profármacos de treprostinil ligados a veículo
MX384234B (es) Uso de pridopidina para el tratamiento de enfermedad de huntington.
CO6400193A2 (es) Dicianopiridinas alquilamino-sustituidas y sus profármacos de éster de aminoácido
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
BR112012023660B8 (pt) usos de uma quantidade terapeuticamente eficaz de um composto, ou de um sal, solvato, hidrato ou pró-fármaco farmaceuticamente aceitável do mesmo para o tratamento de câncer
MX2018003569A (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
EA201792071A2 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
BR112016026552A8 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
BR112013027486A2 (pt) combinação de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor
BR112019005456A2 (pt) composição farmacêutica e método para tratamento de esteatose hepática não alcoólica
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
BR112015014836A2 (pt) método para tratamento alvo de uma ou mais condições do fígado, e, uso oral de uma quantidade terapeuticamente eficaz de pelo menos um análogo de diamidina ou um sal farmaceuticamente aceitável da mesma
BR112015025058A2 (pt) composição farmacêutica capaz de controlar facilmente o padrão de dissolução de lacosamida ou de um sal farmaceuticamente aceitável da mesma
PH12015502717B1 (en) Anti-fibrogenic compounds, methods and uses thereof
BR112014015578A2 (pt) composições farmacêuticas tópicas compreendendo bexaroteno e um corticosteróide
BR112014030288A8 (pt) composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila
MX381932B (es) Composicion intranasal que comprende betahistina.
BR112015031835A2 (pt) agentes terapêuticos para uso na profilaxia e/ou tratamento de distúrbios do movimento hipercinéticos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements